Demyelinating diseases of the central nervous system are characterized by recurrent
demyelination and progressive neurodegeneration, but there are no clinical drugs targeting myelin regeneration or improving functional disability in the treatment of
multiple sclerosis. Total
flavone of Epimedium (
TFE) is the main active components of Epimedium, which exhibits the beneficial biological activities in the treatment of diseases, but there is no report in the treatment of
demyelinating disorder. The purpose of this study was to explore the therapeutic potential and possible mechanism of
TFE in the treatment of
demyelination. The results showed that
TFE efficiently improved the behavioural performance and histological
demyelination in
cuprizone (CPZ)-induced demyelinating model. In terms of action,
TFE increased astrocytes enrichment in corpus callosum, striatum and cortex, and promoted astrocytes to express
neurotrophic factors. Furthermore, the expression of
platelet-activating factor receptor (PAFR) in astrocytes was induced by CPZ feeding and LPS stimulation, accompanied by the increase of inflammatory
cytokines TNF-α,IL-6 and IL-1β.
TFE declined the expression of PAFR, and inhibited inflammatory response. At the same time,
TFE also antagonized PAFR activation and inflammatory response triggered by PAF, which further confirmed that
TFE, as a new PAFR antagonist, inhibited the astrocyte-derived inflammatory response by antagonizing PAFR-
neuroinflammation axis, thus contributing to myelin protection and regeneration.